This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "emphysema_protease_antiprotease_imbalance#Protease-Antiprotease Imbalance"). Key disorder-specific substitutions conforming nodes should make: cigarette-smoke COPD-emphysema enters through oxidant/particulate-driven inflammation with relatively normal alpha-1 antitrypsin levels, whereas alpha-1 antitrypsin deficiency (PiZZ/PiSZ) enters through a primary antiprotease deficit; both converge on unopposed proteolysis of the alveolar wall. Conforming nodes may substitute alveolar macrophage (CL:0000583) for the generic macrophage where the alveolar compartment is emphasized.
Oxidant and Inflammatory Trigger
trigger
Inhaled oxidants and particulates (predominantly cigarette smoke), or in the inherited route a genetic deficiency of alpha-1 antitrypsin, initiate and sustain chronic inflammation of the lower airways and alveoli. This inflammatory program recruits and activates alveolar macrophages and neutrophils, accompanied by a high level of oxidative stress that amplifies the response. This is the conserved upstream trigger from which both the acquired smoking-related and inherited deficiency routes proceed.
Downstream
-
Protease-Antiprotease Imbalance
Protease-Antiprotease Imbalance
amplifier
Activated neutrophils and macrophages release excess serine proteases, chiefly neutrophil elastase, and matrix metalloproteinases. In the acquired route, oxidant inactivation of alpha-1 antitrypsin plus an increased protease burden tips the balance; in the inherited route, severe alpha-1 antitrypsin deficiency leaves elastase unopposed. Across both, the net result is excess unopposed protease activity relative to endogenous antiprotease defenses. This is the central amplifying lesion of the module.
Downstream
-
Alveolar ECM and Elastin Destruction
Alveolar ECM and Elastin Destruction
central effector
Unopposed proteolysis degrades the extracellular matrix of the alveolar wall, with the elastic fiber network surrounding the airspaces being the critical target. Elastolysis and breakdown of collagen disrupt the load-bearing matrix that stores the energy needed for normal expiration. This is the central effector step that translates the biochemical imbalance into structural matrix loss.
Downstream
-
Alveolar Wall Destruction and Airspace Enlargement
Alveolar Wall Destruction and Airspace Enlargement
effector
Progressive loss of the elastic and collagenous matrix leads to distension and rupture of alveolar walls, with loss of elastic recoil and a reduction in the gas-exchange surface area. Alveolar wall cells are lost through injury and apoptosis, and adjacent airspaces coalesce. The result is the structural hallmark of emphysema preceding the named clinical phenotype.
Emphysema
consequence
The permanent enlargement of the distal airspaces (distal to the terminal bronchioles) accompanied by destruction of their walls, without obvious fibrosis. This is the named disease-like phenotype that the protease- antiprotease and oxidant-antioxidant imbalance cascade converges upon, shared by cigarette-smoke COPD-emphysema and genetic alpha-1 antitrypsin deficiency. The clinical consequence is airflow limitation with reduced elastic recoil and impaired gas exchange.